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The human cannabinoid 2 GPCR (hCB2) is a prime
therapeutic target. To define potential cysteine-
related bindingmotifs critical to hCB2-ligand interac-
tion, a library of hCB2 cysteine-substitution mutants
and a novel, high-affinity biarylpyrazole hCB2 antag-
onist/inverse agonist (AM1336) functionalized to
serve as a covalent affinity probe to target cysteine
residues within (or in the microenvironment of) its
hCB2 binding pocket were generated. The data
provide direct experimental demonstration that
both hCB2 TMH7 cysteines [i.e., C7.38(284) and
C7.42(288)] are critical to optimal hCB2-AM1336
binding interaction and AM1336 pharmacological
activity in a cell-based functional assay (cAMP forma-
tion). Elongating the AM1336 aliphatic side chain
generated another novel hCB2 inverse agonist that
binds covalently and selectively to C7.42(288) only.
Identification of specific cysteine residues critical to
hCB2 ligand interaction and function informs the
structure-based design of hCB2-targetedmedicines.
INTRODUCTION
As a cellular communication network ubiquitous in mammals,
the endogenous cannabinoid (endocannabinoid) system influ-
ences diverse physiological processes (Di Marzo, 2009).
Naturally produced cannabinergic lipids act as signaling mole-
cules by engaging and activating at least one of two primary
cannabinoid G protein-coupled receptors (GPCRs), designated
CB1 and CB2. Both display the general architecture of traditional
class-A GPCRs: an extracellular amino terminus; a membrane-
spanning region with seven amphipathic transmembrane helices
(TMHs) connected by intra- (IL) and extracellular loops (EL); and
a cytoplasmic carboxyl terminus. Yet several properties distin-
guish CB1 and CB2, including their limited amino acid identity
(44% overall and 68% within their transmembrane domains),
divergent downstream effector pathways, and distinctive tissue
distributions (Dalton et al., 2009; Di Marzo, 2009).1132 Chemistry & Biology 17, 1132–1142, October 29, 2010 ª2010 ESelective modulation of CB2 signaling has the potential to
address several important medical problems (Poso and
Huffman, 2008). Considerable drug-discovery attention has
been given to CB2 agonists, a reflection of the analgesic effect
of CB2 stimulation and the recent advancement of select CB2
agonists into clinical trials for inflammatory pain (Anand et al.,
2009; Rahn et al., 2008). Although CB2 blockade may promote
certain pathologies (Miller and Stella, 2008), the high level of
constitutive CB2 expression in immune cells, the inducibility of
CB2 expression by injury stimuli even in organs (e.g., brain)
with low constitutive CB2 levels, and the salutary effects of
attenuating CB2 signaling in autoimmune-disease and allergy
models suggest that CB2 antagonists could be important anti-
inflammatory and immunomodulatory drugs (Lunn et al., 2008).
Such findings suggesting the therapeutic potential of pharmaco-
logical CB2 blockade have placed increasing effort toward the
discovery of highly-selective antagonists for the human CB2
GPCR (hCB2).
The integral-membrane, heptahelical nature of traditional
‘‘druggable’’ GPCRs including hCB2 constitutes a formidable
barrier to their direct structural analysis in intact, functionally
active form by classical crystallographic and spectroscopic
methods (Hanson and Stevens, 2009). High-resolution
structures of the vast majority of GPCRs, including CB2 from
any species, are unsolved (Topiol and Sabio, 2009). Conse-
quently, experimental definition of the hCB2 ligand-binding
pocket and the mechanistic relationship between hCB2
conformational transitioning induced by ligand engagement
and the receptor’s functional state is lacking. Computational
(mainly rhodopsin-based) homology models have served as
surrogates for inferring small-molecule pharmacophoric groups
and candidate hCB2 interaction domains (Durdagi et al., 2009;
Tao et al., 1999). The utility of such models to the design of
hCB2-targeted drugs is inherently limited by the low overall
homology among class-A GPCRs and the different biochemical
and molecular characteristics of rhodopsin versus hCB2 (Topiol
and Sabio, 2009; Zhang et al., 2005). Further complicating
definition of hCB2 ligand-binding determinants are the consider-
able interspecies variations in CB2 primary structure and ligand
pharmacology (Liu et al., 2009; Mukherjee et al., 2004) and the
ability of this GPCR to recognize cannabinergic ligands from
a variety of distinct chemical classes, including prototypic
tricyclic ‘‘classical’’ cannabinoids [e.g., the phytocannabinoidlsevier Ltd All rights reserved
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hCB2 GPCR Ligand-Binding Domain()-D9-tetrahydrocannabinol] (D9-THC); the endocannabinoids
anandamide (AEA) and 2-arachidonoylglycerol (2-AG); nonclas-
sical cannabinoids (e.g., CP55940); aminoalkylindols (e.g.,
WIN55212-2); and biarylpyrazoles (e.g., SR144528) (Janero
et al., 2009; Palmer et al., 2002). Experimental characterization
of hCB2 binding sites for privileged structures should facilitate
and inform the design and optimization of therapeutically attrac-
tive hCB2 antagonists, help refine existing CB2 computational
models, and allow prediction of potential off-target activities.
The biarylpyrazole scaffold is particularly germane to the clin-
ical translation of cannabinoid-receptor antagonists as pharma-
cotherapeutics. The first marketed drug to emerge from rational
discovery efforts aimed at therapeutic endocannabinoid-system
modulation is the biarylpyrazole CB1 blocker, rimonabant
(SR141716A) (Janero and Makriyannis, 2009). A rimonabant
analog, the biarylpyrazole SR144528, was the first potent,
selective CB2 antagonist reported (hCB2 Ki = 0.6 nM) (Rinaldi-
Carmona et al., 1998) and has served as an important pharmaco-
logical reagent for probing CB2 function (Janero et al., 2009;
Lunn et al., 2008). Like SR144528, virtually all CB2-selective
antagonists that have been pharmacologically characterized
not only block the effects of exogenous and endogenous
agonists, but also inhibit, at least in cultured cells, constitutive
CB2 activity by virtue of an inverse-agonist action (Lunn et al.,
2008). At (sub)molecular resolution, however, many questions
surround the determinants of hCB2-ligand interaction. In this
regard, the role of cysteine residues is particularly intriguing
(Congreve and Marshall, 2010). Mutational and pharmacological
investigations have implicated select cysteine residues in CB1
protein-protein interactions and post-translational modification
and in CB2 ligand-binding competency and surface expression
(Dainese et al., 2008; Gouldson et al., 2000; Kokkola et al.,
2005; Shire et al., 1999; Zhang et al., 2005). These indirect exper-
imental approaches, however, cannot demonstrate discrete
hCB2-ligand interactions at the amino acid level.
To gain such insight into potential cysteine-related hCB2
ligand-binding motifs, we report application of our multidisci-
plinary experimental approach termed ligand assisted protein
structure (LAPS), which integrates in a complementary fashion
site-directed mutagenesis and the use of chemically-reactive,
high-affinity covalent cannabinoid probes. Prior studies from
this laboratory have established LAPS as a powerful tool for
identifying critical amino acids within enzyme active sites and
orthosteric GPCR ligand-binding regions (Pei et al., 2008; Pi-
cone et al., 2005; Zvonok et al., 2008; Zvonok et al., 2010). In
the present investigation, we have functionalized the aliphatic
side chain of a novel biarylpyrazole SR144528 analog and
hCB2 inverse agonist (AM6731) with an electrophilic isothiocya-
nate (NCS) moiety to generate AM1336, the first covalent hCB2
antagonist/inverse agonist strategically targeted to react
irreversibly with cysteine residues at (or near) its interaction
site (Figure 1A). Systematic application of AM1336 as a mecha-
nism-based covalent affinity probe to a library of single- and
multiple-site hCB2 cysteine-substitution mutants (Figure 1B),
along with a cell-based hCB2 functional assay, allowed us to
interrogate the structural features of hCB2-antagonist interac-
tion and, specifically, identify cysteine residues involved in
hCB2 inverse-agonist engagement and function. Our results
identify two hCB2 TMH7 cysteines, C7.38(284) andChemistry & Biology 17, 1132–1C7.42(288), critical to optimal AM1336 antagonist/inverse
agonist binding and pharmacological activity and two others,
TMH1 cysteine C1.39(40) and IL2 cysteine C137, that influence
hCB2 ligand affinity or AM1336 maximum efficacy, respec-
tively. These data augment the paucity of available experi-
mental information on hCB2/GPCR ligand-binding regions
and inform thereby the rational synthesis of hCB2-targeted
therapeutics.
RESULTS
Generation and Characterization of Heterologously
Expressed Wild-Type and Mutant hCB2s
Stably transfected, polyclonal hCB2-HEK293 cell lines express-
ing either the wild-type (WT) or a cysteine-substitution receptor
mutant were generated. Eight of the ten cysteine residues within
the hCB2 TMHs and loop regions were modified either as single
or double mutagenic lines to yield the hCB2 mutant series
depicted in Figure 1B and listed in Table 1. Two EL2 cysteines,
C174 andC179, were notmutated, for doing so abrogates ligand
binding (Gouldson et al., 2000; Poso and Huffman, 2008; Zhang
et al., 2005). Receptor binding competency was evaluated in
saturation-binding assays carried out on membranes from
each hCB2-HEK239 cell line with [3H]-CP55940 radioligand,
a well-recognized, universal reagent for cannabinoid receptor
profiling in ligand-binding studies (Janero et al., 2009; Poso
and Huffman, 2008). All recombinant WT and mutant hCB2s
were capable of saturable [3H]-CP55940 binding, with specific
binding constituting 70%–90% of total binding, a proportion
that allows reliable quantification of GPCR receptor affinity (Kd)
and population density (Bmax) (Bylund et al., 2004). The
saturation-binding data (Table 1) indicate that hCB2s mutated
in TMH2, IL2, EL2, TMH6, TMH7, or helix 8 (H8) by cysteine-
to-serine (or -alanine) substitution have CP55940 binding
affinities and membrane expression densities at least compa-
rable to those of WT hCB2. The TMH1 mutant, C1.39(40)S,
evidenced 3-fold greater mean Kd (2.47 nM) and Bmax
(5.45 pmol/mg) values as compared to WT hCB2. Membranes
from nontransfected HEK293 cells showed no specific
CP55940 binding, demonstrating the lack of gross, nonspecific
CP55940-membrane interaction (data not shown).
Binding Affinities of WT and Mutant hCB2s for AM1336
The affinities ofWT and cysteinemutant hCB2s for AM1336were
determined in competitive binding assays using [3H]-CP55940.
As a covalent affinity probe (vide infra), AM1336 features an
aliphatic side chain at the N1 pyrazole nitrogen functionalized
with a chemically reactive, electrophilic NCS group that invites,
under our reaction conditions, its irreversible binding to hCB2
cysteine residues at (or immediately adjacent to) the ligand-
binding pocket (Pei et al., 2008; Picone et al., 2005; Zvonok
et al., 2008). Consequently, reported receptor affinities for
AM1336 are considered ‘‘apparent Ki’’ (Ki*) values. Relative to
WT hCB2, the hCB2 C175S, C7.38(284)A, C7.38(284)S,
C7.42(288)A, C7.42(288)S, and C7.38(284)7.42(288)A mutants
exhibited similar AM1336 binding affinities (Table 1). The hCB2
mutants C1.39(40)S, C2.59(89)S, C137S, and C313S evidenced
moderate (2-fold) decreases in affinity for AM1336, whereas
the affinity of the C1.39(40)S mutant was reduced by 3-fold.142, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1133
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Figure 1. Structures of Cannabinoid Ligands and Serpentine Schematic Representation of hCB2
(A) Chemical structures of the principal cannabinoid ligands referred to in the text.
(B) Schematic representation of hCB2. The cysteine residues targeted formutation in this study are denotedwith a bold red circle, and the specificmutants gener-
ated are listed in the boxes above or below each respective locus.
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hCB2 GPCR Ligand-Binding DomainConversely, the binding affinities of C6.47(257)S and the
double mutant C7.38(284)7.42(288)S for AM1336 were in-
creased 2-fold as compared to WT hCB2. The affinity of WT
hCB2 for the nonfunctionalized AM1336 congener, AM67311134 Chemistry & Biology 17, 1132–1142, October 29, 2010 ª2010 E(Ki = 0.63 nM, 95% confidence interval [CI]: 0.44 0.81), was
comparable to its apparent affinity (Ki*) for AM1336 (Table 1).
Thus, the NCS group of AM1336 does not seem to interfere
with its binding to hCB2.lsevier Ltd All rights reserved
Table 1. Ligand-Binding Parameters and AM1336 Binding
Affinities of WT and Cysteine-Mutant hCB2s
Receptor
[3H]-CP55940 AM1336
Kd (nM)
Bmax
(pmol/mg) Ki* (nM)
hCB2 WT 0.62 1.68 0.54
(0.51–0.73) (1.61–1.74) (0.42–0.70)
hCB2 C1.39(40)S 2.47 5.45 2.21
(1.86–3.01) (4.99–5.92) (1.75–2.79)
hCB2 C2.59(89)S 1.03 2.77 1.38
(0.71–1.35) (0.71–1.35) (1.07–1.76)
hCB2 C137S 1.28 1.50 1.81
(0.69–1.86) (1.31–1.70) (1.37–2.39)
hCB2 C175S 0.81 1.69 0.38
(0.65–0.97) (1.61–1.78) (0.32–0.45)
hCB2 C6.47(257)S 0.96 1.58 0.12
(0.78–1.14) (1.50–1.66) (0.10–0.14)
hCB2 C7.38(284)A 0.43 1.15 0.90
(0.21–0.65) (1.03–1.26) (0.69–1.08)
hCB2 C7.38(284)S 0.76 1.28 0.40
(0.58–0.94) (1.21–1.36) (0.25–0.65)
hCB2 C7.42(288)A 0.74 1.93 0.61
(0.36–1.13) (1.69–2.17) (0.48–0.76)
hCB2 C7.42(288)S 1.01 1.07 0.35
(0.79–1.22) (1.01–1.13) (0.28–0.45)
hCB2 C7.38(284)7.42(288)A 0.40 1.12 0.54
(0.24–0.56) (1.04–1.20) (0.42–0.71)
hCB2 C7.38(284)7.42(288)S 1.45 1.38 0.19
(1.09–1.80) (1.28–1.48) (0.14–0.25)
hCB2 C313S 1.18 1.07 1.33
(0.89–1.48) (1.01–1.13) (1.04–1.70)
Kd and Bmax values were derived from saturation-binding assays with
[3H]-CP55940 radioligand. Apparent binding affinities (Ki* values) for
AM1336 were from competitive binding assays with [3H]-CP55940.
Both assays used membrane preparations from stably transfected
HEK293 cells.. Data are the means of at least three independent experi-
ments carried out in triplicate, with 95% confidence intervals shown in
parentheses.
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After 1 h preincubation of hCB2-HEK293 membranes with 5.4
nM AM1336 (i.e., 10-fold the hCB2 Ki* for AM1336; Table 1) at
30C followed by extensive washing to remove unbound ligand,
WT hCB2 displayed a significantly lower (by 60%) mean Bmax
for [3H]-CP55940 relative to parallel ‘‘control’’ membranes not
exposed to AM1336 (Figure 2A). This result indicates that
AM1336 demonstrated a 60% level of irreversible (covalent)
binding to WT hCB2 such that [3H]-CP55940 was subsequently
unable to bind to those pre-occupied receptors. The hCB2
cysteine mutants C1.39(40)S, C2.59(89)S, C137S, C175S,
C6.47(257)S, and C313S exhibited a comparable (53%–70%)
extent of labeling by the AM1336 covalent affinity probe
(Figure 2B). These comparative data allow conclusion that the
specified cysteines in TMH1, TMH2, IL2, EL2, TMH6, and H8
are not critical determinants of AM1336 binding to hCB2.Chemistry & Biology 17, 1132–1In contrast, the TMH7 single-cysteine mutants C7.38(284)A,
C7.38(284)S, C7.42(288)A, and C7.42(288)S all showed signifi-
cantly diminished labeling (28.5%, 33.5%, 39.0%, and 26.5%,
respectively) by the covalent probe relative to control (Figures
2A and 2B). Mutation of both cysteines in TMH7 to alanine or
serine [i.e., in the double mutants C7.38(284)C7.42(288)A or
C7.38(284)C7.42(288)S] abrogated the covalent binding interac-
tion between AM1336 and the receptor (Figures 2A and 2B).
Additionally, preincubation of WT hCB2 with the nonfunctional-
ized (i.e., nonelectrophilic) AM1336 congener (AM6731) that is
unable to bind covalently to hCB2 did not affect the receptor’s
Bmax for [
3H]-CP55940 in a subsequent saturation-binding assay
relative to control (data not shown), indicating that AM1336
does not irreversibly bind to hCB2 in the absence of its NCS
group. In summary, these results provide strong, complimentary
evidence that both TMH7 cysteines, C7.38(284) and C7.42(288),
are sites of covalent attachment of the NCSmoiety of AM1336 to
hCB2 and, hence, are defining elements in the hCB2 binding
landscape of the ligand.
Additional support for the importance of TMH7 cysteine
residues to the hCB2 ligand-binding domain was obtained by
profiling the interaction of WT hCB2 and hCB2 TMH7 cysteine
mutants with AM6720, an AM1336 analog that carries a longer
(by one carbon), NCS-terminal alkyl side chain (Figure 1A). The
binding affinities of WT hCB2 and the hCB2 TMH7 cysteine
mutants [C7.38(284)A, C7.38(284)S, C7.42(288)A, C7.42(288)S,
C7.38(284)7.42(288)A, and C7.38(284)7.42(288)S] for AM6720
were similar (Table 2). Both AM1336 and AM6720 covalently
labeled WT hCB2 to the same, comparably high extent (60%
and 62%, respectively) (Figures 2B and 2C). However, the NCS
moiety in AM6720 reacted with only one [i.e., C7.42(288)], but
not the other [i.e., C7.38(284)], of the two hCB2 TMH7 cysteines
with which AM1336 had reacted (Figure 2C).
Functional Characterization of WT and Mutant hCB2s
hCB2 is negatively coupled via Gi/o to adenylyl cyclase, and CB2
inverse agonists (including SR144528) stimulate cellular forsko-
lin-activated adenylyl cyclase activity (Rinaldi-Carmona et al.,
1998). Thus, cellular cAMP production can be used as a func-
tional assay for hCB2 activity (Bayewitch et al., 1995). AM6731,
AM1336, and AM6720 increased forskolin-stimulated cAMP
production concentration-dependently in cells expressing WT
hCB2 receptor (Figure 3A), indicating that these three biarylpyr-
azole cannabinergic ligands act as hCB2 inverse agonists.
Within a 95% CI, no difference was observed in the inverse-
agonist potency (EC50) of AM1336 among WT hCB2 and the
single- and multiple-site hCB2 cysteine mutants (Table 3).
However, the mean AM1336 maximum efficacy (Emax) for
the C137S mutant and the two double-cysteine TMH7
mutants was 2–3-fold less than the AM1336 Emax for WT
hCB2 (Table 3 and Figure 3B). With respect to WT hCB2,
the EC50 (19.54 nM) and Emax (368.5%) values of the non-func-
tionalized inverse agonist, AM6731, were virtually identical to
those of AM1336 (EC50 = 20.08 nM; Emax = 336.2% [Table 3]).
In contrast, the AM1336 analog with the elongated, NCS-
terminal aliphatic side chain (AM6720) evidenced a greater (by
9-fold) mean EC50 (182.0 nM, 95% CI 131.6–244.0) and
a comparable Emax (404.1%, 95% CI: 378.0–424.2) in compar-
ison to AM1336.142, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1135
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Table 2. Binding Affinities of WT and TMH7 Cysteine-Mutant
hCB2s for AM1336 and AM6720 Using [3H]-CP55940 as the
Radioligand
Receptor
[3H]-CP55940 Ki (nM)
AM1336 AM6720
hCB2 WT 0.54 1.03
(0.42–0.70) (0.85–1.25)
hCB2 C7.38(284)A 0.90 0.92
(0.67–1.21) (0.76–1.11)
hCB2 C7.38(284)S 0.40 0.87
(0.25–0.65) (0.72–1.05)
hCB2 C7.42(288)A 0.61 0.88
(0.48–0.76) (0.72–1.07)
hCB2 C7.42(288)S 0.35 0.73
(0.28–0.45) (0.54–0.98)
Binding affinities were determined in competitive binding assays using
membrane preparations from stably transfected HEK293 cells. Ki values
are the means of at least three independent experiments carried out in
triplicate, with 95% confidence intervals shown in parentheses.
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Figure 3. Concentration-Dependent Increase of Forskolin-Stimu-
lated cAMP Accumulation in HEK293 Cells ExpressingWT or Mutant
hCB2s by Various Inverse Agonists
(A) Comparison among AM1336, AM6731, and AM6720 as inverse agonists of
forskolin (5.0 mM)-stimulated cAMP accumulation in WT hCB2-HEK293 cells.
(B) Comparison of the ability of AM1336 to increase forskolin (5.0 mM)-stimu-
lated cAMP accumulation in HEK293 cells expressing either WT hCB2 or the
hCB2 C137S, C7.38(284)7.42(288)S, or C7.38(284)7.42(288)A hCB2 mutant
receptor. All data shown represent the means ± standard error of means of
at least three independent experiments carried out in duplicate.
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Although structure-function correlates of CB1, CB2, and
peptides representing discrete holoreceptor domains have
been investigated in reconstitution and homology-modeling
studies, the crystal structures of these cannabinoid GPCRs
have been elusive (Mukherjee et al., 2004; Pei et al., 2008; Tiburu
et al., 2009a, 2009b; Zhang et al., 2005). Consequently, hCB2
structural features critical to ligand recognition and binding
remain experimentally ill-defined, the translational importance
of hCB2 as a drug target notwithstanding (Lunn et al., 2008;
Poso and Huffman, 2008). To address this issue directly, we
have used the LAPS experimental approach that we previously
devised and successfully applied to interrogate enzyme and
GPCR structure (Pei et al., 2008; Picone et al., 2005; Zvonok
et al., 2008) along with a novel covalent affinity probe, the
hCB2 biarylpyrazole antagonist/inverse agonist AM1336. An
analog of the CB2 antagonists/inverse agonists SR144528 and
AM6731, AM1336 was rationally designed and functionalized
with an NCS moiety to react with specific amino acid residues
at (or in the immediate microenvironment of) its hCB2 binding
pocket. AM1336 thus represents the first covalent hCB2
antagonist/inverse agonist reported. Because neither the high
affinity of AM1336 for hCB2 nor its EC50 and Emax as an hCB2
inverse agonist differ from those of its direct analog lacking theFigure 2. Labeling of WT and Mutant hCB2s with the Functionalized C
(A and B) Preincubation with AM1336 limits subsequent [3H]-CP55940 binding t
either a reduction in the level of covalent labeling by AM1336 from this maximum [
quent binding of [3H]-CP55940, or no AM1336 covalent labeling [C7.38(284)7.42(
binding. Membranes prepared fromHEK293 cells expressing either theWT or a de
Ki* value) for 1 h at 30
C and washed extensively to remove noncovalently asso
binding assay using [3H]-CP55940 as the radioligand. (A) Saturation-binding curve
with AM1336 as described above (blue line) and control membranes processed in
difference in the [3H]-CP55940 Bmax values of each hCB2 receptor, designated a
with AM1336.
(C) Covalent labeling of WT and select hCB2 mutant receptors with AM6720 at
All data shown represent the means with 95% confidence intervals of at least th
Chemistry & Biology 17, 1132–1NCS moiety (i.e., AM6731), AM1336’s chemically-reactive NCS
group does not interfere with its binding to or functional interac-
tion with hCB2.
As demonstrated previously for the LAPS paradigm with other
NCS-functionalized cannabinoid probes (Pei et al., 2008; Picone
et al., 2005; Zvonok et al., 2008), although lysine is in principle
capable of interactingwith anNCS group, the lysine amino group
represents a significantly weaker nucleophile than the highly
nucleophilic cysteine thiol under our reaction conditions (Picone
et al., 2005). The potential for significant interaction betweenovalent Affinity Probe AM1336 or AM6720
o WT hCB2 (i.e., reduces the Bmax) by 60%. Select mutant hCB2s evidence
C7.38(284)A, C7.38(284)S, C7.42(288)A, C7.42(288)S], allowing greater subse-
288)A and C7.38(284)7.42(288)S], allowing maximal subsequent [3H]-CP55940
signated mutant hCB2 were preincubated with 5.4 nM AM1336 (i.e., 10-fold its
ciated AM1336. The washed membranes were then subjected to a saturation
s using [3H]-CP55940 for WT and select mutant hCB2 receptors preincubated
parallel, but without prior AM1336 exposure (black line). (B) Comparison of the
s percent receptor covalent labeling by AM1336 with or without preincubation
C7.42(288), but not C7.38(284), assessed with the protocol described above.
ree independent experiments carried out in duplicate.
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Table 3. Increase of Forskolin-Stimulated cAMP Accumulation in
Cells Expressing WT or a Cysteine-Mutant hCB2
AM1336
Emax (%)EC50 (nM)
hCB2 WT 20.08 336.2
(12.21–35.50) (305.7–366.8)
hCB2 C1.39(40)S 59.31 375.9
(28.27–124.4) (324.3–427.5)
hCB2 C2.59(89)S 42.95 455.5
(30.38–60.70) (427.1–484.0)
hCB2 C137S 27.79 179.3
(16.94–45.58) (163.8–194.7)
hCB2 C175S 27.93 301.6
(21.58–36.18) (288.0–315.1)
hCB2 C6.47(257)S 36.27 435.4
(18.71–70.32) (384.0–486.7)
hCB2 C7.38(284)S 38.28 270.4
(22.44–65.27) (244.0–296.7)
hCB2 C7.42(288)S 30.63 233.8
(13.64–68.74) (200.6–267.0)
hCB2 C7.38(284)7.42(288)A 27.38 179.5
(16.75–44.75) (162.3–196.8)
hCB2 C7.38(284)7.42(288)S 7.49 129.0
(3.62–15.50) (114.4–143.6)
hCB2 C313S 19.44 513.8
(10.62–35.59) (461.3–566.4)
cAMP assays were carried out using cells from stably transfected hCB2-
HEK293 WT and mutant lines. Data are mean EC50 and Emax values from
at least three independent experiments carried out in triplicate with 95%
confidence intervals shown in parentheses.
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fact that the only lysines modeled within the putative hCB2
binding pocket are in TMH3, a region unlikely on topological
grounds to associate with the aliphatic side chain of a cannabi-
noid ligand (Chen et al., 2006; Gouldson et al., 2000). Indeed,
we have recently demonstrated that the conserved hCB2
TMH3 lysine, K3.28(109), does not interact with the alkyl chain
of AM841, a potent CB agonist and CP55940 analog (Pei et al.,
2008).
Along with a high-affinity covalent probe, proteins that carry
defined point mutations are other components of our LAPS
experimental paradigm. In the current work, global cysteine to
serine (and/or alanine) substitutions across hCB2 TMHs and
two loop regions (IL2, EL2) allowed direct experimental assess-
ment of the contribution of each cysteine to the hCB2 binding
motif, as probed with AM1336. The hCB2 TMHs and loop
regions contain a total of ten cysteines (Figure 1B). We elected
not to mutate C174 and C179 in EL2 that apparently form a crit-
ical disulfide bridge essential to hCB2 ligand binding (Gouldson
et al., 2000; Poso and Huffman, 2008; Zhang et al., 2005). The
remaining eight were mutated to serine, both individually and,
for the two TMH7 cysteines, in tandem. Introduction of serine
into TMH7 by mutagenesis at C7.38(284) and/or C7.42(288)
could invite interhelical hydrogen-bond formation between their1138 Chemistry & Biology 17, 1132–1142, October 29, 2010 ª2010 Eside chains and nearby peptide-backbone carbonyl oxygens,
leading to receptor deformation and artifactual alteration of its
ligand-accommodation characteristics (Deupi et al., 2004).
To obviate this potential problem, we also mutated these
TMH7 cysteines to alanines. The comparable nature of the
CP55940 and AM1336 binding profiles between the hCB2
TMH7 serine and alanine substitution mutants makes it unlikely
that spurious, short-distance amino acid interactions were
introduced as a result of the TMH7 cysteine-to-serine substitu-
tions made. Because cysteine and serine are very conservative,
isosteric analogs of each another and are characterized by polar,
uncharged side chains, whereas alanine has a smaller, nonpolar
aliphatic (i.e., methyl) side chain, this result further suggests that
amino acid polarity and/or ligand side-chain bulk at TMH7
positions C7.38(284) and C7.42(288) do not appreciably influ-
ence hCB2-ligand interaction.
All hCB2 cysteine-substitution mutants generated demon-
strated high binding affinities, favorable expression densities,
and substantial (>70% total binding) specific binding in a stan-
dard saturation-binding assay using isolated cell membranes
and [3H]-CP55940 radioligand. Thus, the cysteine substitutions
did not appear to compromise overall hCB2 structure, with the
possible exception of the hCB2 C1.39(40)S mutant, which
evidenced a somewhat lower CP55940 Kd as compared to WT
hCB2. The comparable CP55940 binding affinities of the
C7.38(284) and C7.42(288) single and double mutants suggest
that these two TMH cysteine residues do not act synergistically.
Furthermore, all hCB2 mutant receptors generated were
functionally responsive to exogenously-introduced CB2 ligands
in intact HEK293 cells, as evidenced by their effective signal
transmission in a cell-based cAMP assay. Although we did not
demonstrate directly (with, e.g., fluorescent probes [Dunham
and Hall, 2009]) surface hCB2 expression in our HEK293 cell
system, these data suggest that the proper trafficking dynamics
and plasma-membrane disposition within HEK293 cells had
occurred for the WT and hCB2 cysteine mutants studied. In
contrast, Zhang et al. (2005) observed that hCB2 C1.39(40)S
[and C4.67(175)A] mutants did not target the cell membrane in
their HEK293-based expression system, a difference that could
reflect, for example, a deficit of receptor-trafficking chaperones
and/or accessory interacting proteins under their experimental
conditions (Dunham and Hall, 2009; Niehaus et al., 2007) as
well as compromised expression levels in their transfected
constructs over time (Bjo¨rk et al., 2005).
Virtually all of the hCB2 cysteine-substitution mutants
exhibited an AM1336 Ki* comparable to that of WT hCB2. There-
fore, the AM1336 binding site remained largely unaffected by
these amino acid replacements, and no synergistic effect
between the two TMH7 cysteine residues was apparent with
respect to the hCB2-AM1336 molecular interaction. The largest
difference in AM1336 binding affinity was evident between WT
hCB2 and the C1.39(40)S mutant (Ki* values of 0.54 nM and
2.21 nM, respectively). This difference in AM1336 affinity, along
with the difference in Kd of similar magnitude between WT hCB2
and the C1.39(40)S mutant for the nonclassical cannabinoid,
CP55940, suggest that the C1.39 residue plays a permissive
role in hCB2 binding of nonclassical and aminoalkylindole
cannabinoid ligands. This result further illustrates the ability of
CB2 to engage small molecules from several different chemicallsevier Ltd All rights reserved
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binding domains that may converge to varying extents and be
influenced by similar, but not necessarily identical, factors at
the molecular level (Janero et al., 2009; Lunn et al., 2008; Palmer
et al., 2002; Pei et al., 2008; Poso and Huffman, 2008).
This study used the nonfunctionalized direct AM1336
congener, AM6731, as the control ligand, an approach conso-
nant with the use of small-molecule probes in chemical biology
to explore protein structure/function (Frye, 2010). Prior work
(Pei et al., 2008) demonstrates that: (1) the affinities of WT
hCB2 and the hCB2C6.47(257)Smutant for the tricyclic classical
cannabinoid agonist D9-THC are comparable in competitive
binding assays with either [3H]-CP-55940 or [3H]-WIN55212-2;
and (2) the hCB2 C6.47(257)S mutant, relative to WT hCB2,
displays a significantly increased (by 2-3-fold) affinity for the biar-
ylpyrazole inverse agonist SR144528 in a competitive binding
assay with [3H]-WIN55212-2. These results help place the recent
findings with AM1336 into a broader ligand context. Specifically,
the hCB2 C6.47(257)S mutant shows an increased affinity for
both inverse agonists SR144528 (Pei et al., 2008) and AM1336
(Table 1), whereas mutation of this TMH6 cysteine residue did
not alter the receptor’s affinity for D9-THC agonist (Pei et al.,
2008). These comparative data suggest that some features of
the hCB2 binding site may be shared between AM1336 and
other hCB2 biarylpyrazole inverse agonists, but not with clas-
sical tricyclic agonists. The suggestion notwithstanding, over-
lapping cannabinoid GPCR binding sites for ligands of different
chemical structures need not be identical (Gouldson et al.,
2000). This concept is noteworthy here, for the chemical struc-
ture of AM1336 is changed significantly from that of SR144528
through replacement of the latter’s aromatic (4-methylphenyl)
methyl substituent at the N1 pyrazole nitrogen with an NCS-func-
tionalized alkyl chain. Future experimental definition of the
optimal binding poses and their determinants for a wide variety
of hCB2 agonists/antagonists with divergent chemical struc-
tures would assist the rational design of hCB2 ligands as
pharmacologically attractive drugs with, perhaps, functional
selectivity downstream from hCB2. Our LAPS approach, supple-
mented by modeling studies with AM1336, AM6731, and other
(covalent) ligands along with progressive refinement of extant
CB2 homology models (Durdagi et al., 2009; Pei et al., 2008),
offers a tenable route to such data.
We previously demonstrated the importance of hCB2 C6.47
(257) to the remarkable potency of an NCS-derivatized classical
cannabinoid agonist, AM841, a phenomenon that directly
reflects covalent AM841 binding to that TMH6 residue
(Pei et al., 2008). The present study offers experimental demon-
stration that two TMH7 cysteine residues [i.e., C7.38(284) and
C7.42(288)] can establish a productive binding interaction
between hCB2 and the NCS-functionalized covalent affinity
probe and inverse agonist, AM1336, without enhancing its
inverse-agonist activity relative to the nonderivatized parent,
AM6731. An AM1336 analog with a longer, NCS-functionalized
alkyl tail (AM6720) interacts only with C7.38(284), which is
positioned further down in the TMH7 bundle. Although the role
of hCB2 C6.47(257) in AM841 binding is similar to that of hCB1
C6.47(355) (Pei et al., 2008), the involvements of hCB2
C7.38(284) in AM1336 binding and hCB2 C7.42(288) in
AM1336 and AM6720 binding have no apparent direct correlatesChemistry & Biology 17, 1132–1in hCB1. These results further support our previous contention
(Pei et al., 2008) that both the binding domains of hCB2 ligands
with distinct pharmacological modes of action as well as
differences in ligand-binding motifs between hCB1 and hCB2
can be distinguished at the amino acid level with our LAPS
experimental approach. This view is further substantiated by
our finding that hCB1 does not bind AM1336 irreversibly (data
not shown), suggesting that the hCB1 and hCB2 ligand-binding
domains differ with respect to critical cysteine residues.
Results from a cell-based cAMP assay substantiate that WT
and mutant hCB2s retain functionality when overexpressed in
our HEK293 cell system. Although it is not the aim of the current
work to detail the pharmacology and cellular signaling route(s) of
the WT or cysteine mutant hCB2s in HEK293 cells, the cAMP
data offer provisional functional evidence that the high-affinity
AM1336 probe displays an inverse-agonist action against the
WT and hCB2 cysteine point mutants studied. In a saturation-
binding assay with CP55940, expression densities were at least
comparable among the WT and all mutant hCB2s, notably
including the two mutant receptors identified by LAPS as having
point-mutations in cysteines critical to probe (AM1336) interac-
tion [i.e., C7.38(284)and C7.42(288)] (Table 1). Both the naive
parental HEK cells and the HEK cells transfected with and
overexpressing either WT and any hCB2 mutant contain very
low amounts of cAMP (data not shown); neither forskolin nor
AM1336 affects the low cAMP content of naive parental HEK
cells not overexpressing WT or mutant hCB2 (data not shown);
and the hCB2-HEK293 cAMP experiments described herein
were conducted in the absence of exogenous hCB2 agonist.
These characteristics of our cell-based hCB2 expression system
render the forskolin cAMP response we observe indicative of the
constitutive activity of WT and mutant hCB2s (Jansson et al.,
1998; Kozell and Neve, 1997; Shryock et al., 1998). Indeed, it
is likely that the amplifying action of forskolin on adenylyl cyclase
allied to hCB2 overexpression enabled us to detect the constitu-
tive receptor activity (Kollias-Baker et al., 1997). In HEK cells
overexpressing either WT or any mutant hCB2, 5.0 mM forskolin
strongly stimulates cellular cAMP production, bringing the
cellular cAMP content in each hCB2-HEK293 cell construct to
a comparably high level before AM1336 exposure, and
AM1336 effectively stimulates the forskolin-potentiated cAMP
formation in HEK cells overexpressing either WT or any mutant
hCB2 with equivalently high (nanomolar) potency (IC50 data in
Table 3). If there were differences in constitutive activity between
the WT and mutant hCB2s as overexpressed in the HEK cells,
the 5.0 mM forskolin treatment would have resulted in markedly
disparate levels of cAMP at stimulated baseline among cells
expressing the WT or a mutant hCB2, which was not the case.
Furthermore, the AM1336 functional sensitivity would be highly
variable among WT and mutant receptors, counter to the
observed, comparable EC50’s of this high-affinity CB2 ligand
against both the WT and all mutant hCB2s in the cellular cAMP
assay (Table 3). Based on this reasoning as supported by
literature precedent in other cell-based cAMP assay systems
overexpressing WT and mutant/subtype GPCRs (Ben-Shlomo
et al., 2009; Benned-Jensen and Rosenkilde, 2008; Portier
et al., 1999; Shen et al., 2006; Wieland et al., 2001), we conclude
from the aggregate cAMP data that the constitutive functional
activity of WT hCB2 is conserved and displayed to a similar142, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1139
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such that the potentiation of forskolin-stimulated cAMP in
HEK293 cells overexpressing each receptor by AM1336 is
suggestive of an inverse-agonist property of this high-affinity
hCB2 chemical probe.
The hCB2 cysteine-to-serine substitutions did not significantly
change AM1336’s inverse-agonist potency (indexed as EC50).
The fact that the AM1336 NCS group reacts with either hCB2
C7.38(284) or C7.42(288) and maintains full pharmacological
function of the ligand implies that this region of the hCB2 binding
pocket exhibits a degree of structural plasticity. The ligand
accommodation capability of this region, however, may be
circumscribed, for themaximal AM1336 inverse-agonist efficacy
(indexed as Emax) was moderately decreased in the double
C7.38(284)7.42(288)A and C7.38(284)7.42(288)S mutants. It is
unlikely that the lower AM1336 Emax of the C7.38(284)C7.42
(288)A and C7.38(284)C7.42(288)S double mutants reflects
a compromised covalent interaction between these receptors
and AM1336, for the non-functionalized analog of AM1336 that
does not covalently bind to hCB2 (AM6731) exhibited an Emax
(and EC50) comparable to that of AM1336. Rather, the fact that
WT hCB2 evidenced a much higher (9-fold) EC50 and similar
Emax for the AM1336 analog with a longer side chain (AM6720)
as compared to AM1336 itself suggests that a functionally
optimal binding interaction of this family of antagonist/inverse
agonist ligands with hCB2 involves a binding domain that most
readily accommodates an aliphatic side chain of five carbons
in length and involves a TMH7 binding interaction with either
C7.38(284) or C7.42(288). Maximal AM1336 inverse-agonist
efficacy (Emax) was also decreased in the single hCB2 C3.56
(137)S mutant. The C3.56(137) residue, which is located down-
stream from the highly-conserved DRY (Asp-Arg-Tyr) motif at
the cytoplasmic terminus of TMH3, has been generally
implicated in the interactions between GPCRs and G protein
subunits that support information relay from the extra-to the
intracellular compartment (Feng and Song, 2003). Therefore,
mutating C3.56(137) may have limited the receptor’s function-
ality such that antagonist interaction with it would elicit at most
a dampened maximal effect.
SIGNIFICANCE
The hCB2 receptor is emerging as one of the most inter-
esting GPCR drug targets in translational biomedicine.
Antagonists of hCB2-mediated signal transmission hold
therapeutic potential as immunomodulatory and anti-in-
flammatory drugs. Yet hCB2 remains intractable for high-re-
solution structure determination. Thorough understanding
of the molecular interactions between hCB2 and small-
molecule, high-affinity orthostericmodulators would greatly
facilitate the rational design and therapeutic exploitation of
hCB2-targeted antagonists. Despite extant data from phar-
macological structure-activity studies and homology
modeling, direct experimental hCB2 structural information
is lacking. The present work has used our LAPS experi-
mental paradigm integrating a chemically selective affinity
probe as the first covalent hCB2 antagonist/inverse agonist
(AM1336) and site-directed mutational analysis. These
complimentary approaches have enabled us to define the1140 Chemistry & Biology 17, 1132–1142, October 29, 2010 ª2010 Erole of cysteine residues in the interaction of this biarylpyra-
zole ligand with functionally-active hCB2. Our data directly
demonstrate the influence of C1.39(40) and C137 and the
importance of C7.38(284) and 7.42(288)S residues in hCB2
ligand recognition and optimal pharmacological antago-
nism/inverse agonism by AM1336. We have also identified
specific hCB2 features at the amino acid level affecting
hCB2-ligand interaction and function not shared by CB1.
These results help inform the rational design of targeted,
selective hCB2 small-molecule modulators with therapeutic
potential. The data supplement the very limited experimen-
tally-derived structural detail for GPCRs, cell-surface mole-
cules constituting the largest family of proteins in the human
genome and one of the most frequently addressed classes
of drug targets.EXPERIMENTAL PROCEDURES
Materials
Sources are given in the Supplemental Experimental Procedures available on-
line.Amino Acid Numerical Descriptor
Amino acid residues in hCB2 TMHs are numbered using amodified Ballesteros
andWeinstein (1995) system. The most highly conserved residue in each TMH
is assigned a locant of 50. This number is preceded by the TMH number and
followed in parentheses by the sequence number. All other residues in any
given TMH are numbered relative to this residue.Site-Directed Mutagenesis, Cell Transfection and Culture,
and Transgene Integrity
The partial-length cDNA encoding the hCB2 translated region was kindly
provided by Dr. Sean Munro (MRC Laboratory of Molecular Biology, Cam-
bridge, UK). Techniques utilized to construct hCB2 mutants and express WT
and mutant hCB2s in HEK293 cells were essentially those detailed (Pei
et al., 2008), as described in the Supplemental Experimental Procedures.Cell Membrane Preparation and Receptor Binding Assays
After cell disruption by cavitation in a pressure cell at 65 Torr, cell membranes
were isolated by ultracentrifugation and stored at 70C (Xu et al., 2005).
Receptor ligand-binding assays were essentially as described (Lan et al.,
1999; Pei et al., 2008) and detailed in the Supplemental Experimental
Procedures.Receptor Affinity Labeling
Covalent affinity labeling was carried out with hCB2-HEK293 membranes
prepared as described above. Membrane (1 mg protein/ml) in TME-BSA
was allowed to equilibrate with either an NCS-derivatized ligand (i.e.,
AM1336 or AM6720) or the underivatized, direct analog of AM1336 (i.e.,
AM6731) as negative control for 1 h at 30C with agitation (total volume,
2.5 ml). Final ligand concentration was 10-fold its respective Ki. The reaction
mixture was centrifuged at 27,000 3 g, 30C, and the resulting membrane
pellet was washed three times with 10 ml TME-BSA at 30C to remove any
unbound ligand. The membranes were allowed to equilibrate at 30C in
25 ml TME-BSA for 15 min between each wash. Next, three final washes
were conducted with the same protocol, but with BSA-free TME. Saturation-
binding assays were then carried out with the washed membranes and
[3H]-CP55940 radioligand, and the Bmax for each membrane sample was
calculated, as described above. Percent covalent labeling was calculated
as: {[Bmax(control)  Bmax(labeled)]/Bmax(control)} 3 100. The Bmax(control) for
[3H]-CP55940 was determined by conducting the assay exactly as described,
but in the absence of test ligand (i.e., AM1336, AM6720, or AM6731).lsevier Ltd All rights reserved
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Receptor functionality was indexed as cAMP formation in a cell-based
bioassay modified from Tao et al. (1999) and detailed in the Supplemental
Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and can be found with this article online at doi:10.1016/j.chembiol.2010.08.
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